Status:
UNKNOWN
Cardiovascular Morbidities and Lung Cancer Treatment: a Prospective Registry
Lead Sponsor:
European Lung Cancer Working Party
Conditions:
Lung Neoplasm
Eligibility:
All Genders
18+ years
Brief Summary
Therapeutic algorithms for lung cancer are mainly based on randomised controlled trials which excluded patients with severe co-morbidities. Smoking, the main risk factor for lung cancer, is associated...
Eligibility Criteria
Inclusion
- Histological diagnosis of lung cancer, either NSCLC or SCLC patients and carcinoid tumours
- Untreated lung cancer of any stage and any treatment (including palliative care only).
- Availability for participating in the detailed follow-up of the protocol.
- Signed informed consent.
- Age above 18 years.
- Presence of at least one co-morbidity:
- Any active or past cardiac ischemia
- Reduced left ventricular ejection fraction (\< 50%)
- Obstructive cardiomyopathy
- Valvular dysfunction (3 or 4/4; valvular replacement)
- Arrhythmia (atrial flutter or fibrillation, significant ventricular arrhythmia, 2nd-3rd degree auriculo-ventricular block, Wolf-Parkinson-White and other similar aberrant conduction, bifascicular block, arrhythmogenic right ventricular dysplasia)
- Uncontrolled hypertension (systolic blood pressure (BP) \> 160 millimeter of mercury (mmHg) or diastolic BP \> 100 mmHg on ≥ 1 hypotensive drug) or controlled hypertension on ≥ 2 concurrent hypotensive drugs
- Active or treated peripheral arteritis (grade 2 or more)
- Cerebrovascular events
- Pulmonary embolism and/or thrombophlebitis or patients at high risk of thrombophilia (homozygous Leiden factor…)
- Aortic aneurism
Exclusion
- Thymoma and thymic malignancies, pleural mesothelioma.
- Patient previously treated for lung cancer.
- Tumours for which complete staging cannot be assessed.
- History of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or of the bladder or cured malignant tumour (more than 5-year disease free interval).
Key Trial Info
Start Date :
December 4 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03368820
Start Date
December 4 2017
End Date
December 31 2023
Last Update
August 23 2021
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet
Brussels, Belgium, 1000
2
Hôpital Saint-Joseph
Charleroi, Belgium
3
CHU Tivoli
La Louvière, Belgium
4
Hôpital Ambroise Paré
Mons, Belgium